Targeted drug delivery strategies to treat lung metastasis

被引:30
作者
Bar, Jair
Herbst, Roy S. [1 ]
Onn, Amir [2 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Sect Thorac Med Oncol, Dept Thorac Head & Neck Med Oncol, Houston, TX 77230 USA
[2] Chaim Sheba Med Ctr, Inst Pulm Physiol, IL-52621 Tel Hashomer, Israel
关键词
aerosol; antibody-conjugated; enhanced permeability and retention; ligand-targeted therapy; liposomes; magnetic targeting; nanoparticle; polymer conjugates; vascular targeting agents; POLYMER-BOUND DOXORUBICIN; ADVANCED SOLID TUMORS; AEROSOL GENE-THERAPY; PHASE-III TRIAL; IN-VIVO; BREAST-CANCER; INTRACELLULAR DELIVERY; PACLITAXEL POLIGLUMEX; PULMONARY METASTASES; NONVIRAL DELIVERY;
D O I
10.1517/17425240903167926
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Most cancer patients die of metastatic disease, and in a high proportion of cases, from lung metastasis. Methods to target therapy to metastatic disease in general and specifically to lung metastasis are required. Objective: To describe the current and potential tools for the treatment of lung metastasis. Methods: Literature search tools were used with no predefined limitations to encompass the main tumor targeting methods. Methods in standard clinical use, in clinical trials and in preclinical development are reviewed. Data about treatment of lung metastasis and solid tumors are emphasized. Results: Physically targeting therapies to lung metastasis is feasible by aerosol-carried agents, magnetic targeting and intravascular devices. Biological targeting includes methods such as polymers and liposomes, which are based on the principle of enhanced permeability and retention of large molecules in tumor vascular field. Ligand-targeted treatments depend on cancer-specific antibodies or receptors. Few of these methods are in clinical trials or in standard clinical use. However, promising techniques are in advanced preclinical or early clinical studies. The authors believe that targeted treatments will be one the major anticancer tools in the near future.
引用
收藏
页码:1003 / 1016
页数:14
相关论文
共 90 条
[1]   PIONEER: A phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2 [J].
Albain, Kathy S. ;
Belani, Chandra P. ;
Bonomi, Philip ;
O'Byrne, Kenneth J. ;
Schiller, Joan H. ;
Socinski, Mark .
CLINICAL LUNG CANCER, 2006, 7 (06) :417-419
[2]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .4. PROGNOSTIC FACTORS IN 200 MELANOMA PATIENTS WITH DISTANT METASTASES (STAGE III) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
SMITH, JW ;
MADDOX, WA ;
DURANT, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) :126-134
[3]   Amphiphilic triblock copolymer poly(p-dioxanone-co-L-lactide)block-poly(ethylene glycol), enhancement of gene expression and inhibition of lung metastasis by aerosol delivery [J].
Bhattarai, S. R. ;
Kim, S. Y. ;
Jang, K. Y. ;
Yi, H. K. ;
Lee, Y. H. ;
Bhattarai, N. ;
Nam, S-Y ;
Lee, D. Y. ;
Kim, H. Y. ;
Hwang, P. H. .
GENE THERAPY, 2007, 14 (06) :476-483
[4]   ERADICATION OF LARGE SOLID TUMORS IN MICE WITH AN IMMUNOTOXIN DIRECTED AGAINST TUMOR VASCULATURE [J].
BURROWS, FJ ;
THORPE, PE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8996-9000
[5]   Reversibly stable thiopolyplexes for intracellular delivery of genes [J].
Cavallaro, Gennara ;
Campisi, Monica ;
Licciardi, Mariano ;
Ogris, Manfred ;
Giammona, Gaetano .
JOURNAL OF CONTROLLED RELEASE, 2006, 115 (03) :322-334
[6]  
CROW J, 1981, CANCER-AM CANCER SOC, V47, P2595, DOI 10.1002/1097-0142(19810601)47:11<2595::AID-CNCR2820471114>3.0.CO
[7]  
2-Q
[8]   Targeted delivery of magnetic aerosol droplets to the lung [J].
Dames, Petra ;
Gleich, Bernhard ;
Flemmer, Andreas ;
Hajek, Kerstin ;
Seidl, Nicole ;
Wiekhorst, Frank ;
Eberbeck, Dietmar ;
Bittmann, Iris ;
Bergemann, Christian ;
Weyh, Thomas ;
Trahms, Lutz ;
Rosenecker, Joseph ;
Rudolph, Carsten .
NATURE NANOTECHNOLOGY, 2007, 2 (08) :495-499
[9]   PHASE-I CLINICAL AND PHARMACOKINETIC TRIAL OF DEXTRAN CONJUGATED DOXORUBICIN (AD-70, DOX-OXD) [J].
DANHAUSERRIEDL, S ;
HAUSMANN, E ;
SCHICK, HD ;
BENDER, R ;
DIETZFELBINGER, H ;
RASTETTER, J ;
HANAUSKE, AR .
INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) :187-195
[10]   Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer [J].
Danson, S ;
Ferry, D ;
Alakhov, V ;
Margison, J ;
Kerr, D ;
Jowle, D ;
Brampton, M ;
Halbert, G ;
Ranson, M .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2085-2091